Metastatic (Stage IV) Breast Cancer Treatments

Executive Summary

The different standard treatments for metastatic breast cancer are explained in detail. Standard treatments are used along with the integration of effective treatment planning. Clinical trials are used as an innovative treatment approach that combines different therapies and drugs for treating metastatic breast cancer. Metastatic breast cancer is the stage IV of breast cancer that metastasizes to other body parts such as bone, liver and lungs. The treatment options for metastatic breast cancer include hormone therapy, chemotherapy, and immunotherapy that help the patients endure pain and help them live longer by compressing the tumor or reducing the maturity rate. The receptor and the HER2 status of cancer play a vital role in selecting the type of drug used for Stage IV breast cancer.

Palliative care is provided to the patients to cope with mental, physical or financial issues while involving medication, nutritional changes, emotional and spiritual support and other relaxation therapies. Various pharmacological treatments are integrated for destroying the tumor cells. Medicament analysis is carried out to determine cancer cells’ reactivity to the drugs. Blood testing for tumor markers is used for assessing metastatic breast cancer. The antibody conjugates, including Trop-2 antibody-drug conjugates and sacituzumab govitecan, are used for metastatic breast cancer treatment.

Treatment of Metastatic Breast Cancer

When breast cancer matures and spreads, it spreads rapidly to several different body parts such as the bones, liver and lungs.

Sometimes the brain and other parts as well get affected. 

There are several different treatment options for Metastatic Breast Cancer which include ​1​

  • Hormone Therapy
  • Chemotherapy
  • Immunotherapy

Sometimes it can also include a blend of the above.

These Metastatic Breast Cancer treatments help patients endure pain and help them live longer by compressing the tumor or reducing the maturity rate. These tumors can lead to death. 

The receptor and the HER2 status of cancer play a vital role in selecting the type of drug used for Stage IV breast cancer. 

Hormone receptor-positive cancers

Hormone treatments for Metastatic Breast Cancer are usually used to treat patients with hormone receptor-positive malignancies (oestrogen receptor-positive or progesterone receptor-positive) (tamoxifen or an aromatase inhibitor) ​2​. It could be associated with a particular medicine such as a CDK4/6 inhibitor, everolimus, or PI3K inhibitor. As hormone therapy is a long process and takes a few months, chemo is frequently the go-to treatment for patients with severe issues from their cancer maturity, such as breathing problems.

Hormone receptor-negative cancers

Chemotherapy is the primary medication for women with hormone receptor-negative (ER-negative and PR-negative) malignancies, as hormone therapy is ineffective in these cases ​3​

HER2-positive cancers

If administered with chemotherapy or other medications like hormone therapy or other anti-HER2 therapies, trastuzumab (Herceptin) may assist the patients with HER2-positive malignancies to live longer. One more targeted medicine, pertuzumab (Perjeta), could be added. Targeted medications like lapatinib (which may be used in conjunction with some chemotherapies or hormone therapy) or ado-trastuzumab emtansine are two additional alternatives (Herceptin).

HER2-negative cancers in women with BRCA gene mutation:

Chemotherapy is usually used to treat the patients (If detected as hormone receptor-positive, then hormone therapy is more suited). Treatment with a targeted drug known as a PARP inhibitor, for example, olaparib or talazoparib (talzenna), is an option after the completion of chemotherapy.

HER2-negative breast cancers in women with a PIK3CA mutation

Piqray is a PI3K inhibitor that can be combined with fulvestrant (faslodex) to treat advanced hormone receptor-positive breasts.

Triple-negative breast cancer (TNBC)

In patients with advanced triple-negative breast cancer whose tumor gives rise to the PD-L1 protein, the immunotherapy drug atezolizumab (Tecentriq) can be administered with albumin-bound paclitaxel (Abradant). (About 1/5th of triple-negative breast tumors include the PD-L1 protein) ​4​. Other chemo called platinum medicines (such cisplatin or carboplatin) are advised for patients with TNBC and a BRCA mutation whose cancer no more reacts to standard breast cancer chemo medications.

Hope – Hidden but not lost

Sometimes all of this is too much to carry mentally, physically and emotionally; analyzing the priorities and goals in life can be crucial. The patients are suggested/advised to talk to their GP s or personal nurses about their quality of life. It is sometimes very positive and a blessing as it helps determine the best possible medication for the respective individual. Consider how each therapy choice is aligned with your merits and beliefs, family situation, financial status and anything else that matters to you at this time of distress. Connecting with a support group might also assist you in communicating these problems.

Metastatic breast cancer – Observation

For metastatic breast cancer, tumors can react to various pharmacological therapies. It indicates that the medications can reduce or destroy tumors. It can, however, develop resistance or stop responding to drugs used to treat metastatic breast cancer over a prolonged period. For metastatic breast cancer, tumors can react to various pharmacological therapy. It indicates that the medications can destroy tumors. For metastatic breast cancer, tumors can respond to multiple pharmacological treatments. It suggests that the drugs can destroy tumors.

Some metastatic breast cancer cells grow to require specific proteins or cell pathways. For a limited time, drugs that target specific proteins or pathways can delay or stop the growth of cancer cells.

Medicament Analysis

Proteins can be something of a match with the journey taken in a ghat section. Breast cancer cells must pass through the tunnels to continue taking the same.

If a blockage (such as a medicine that targets the protein) is encountered, the cancer cell will be unable to continue down the same path. However, the cancer cell eventually finds a way past the obstruction and takes a different channel to develop.

When a patient is undergoing cancer medication, It’s natural to show nerves just before the scans or other testing to determine how cancer reacts to the drug. It is known as scan anxiety. A patient and their family needs to manage this. 

If it helps, talk to your loved ones, friends, or someone you are comfortable with. If possible, bring them to the GP with you. Meditation can also play a vital role.

Blood tests for tumor markers

Blood testing for tumor markers may assess metastatic breast cancer in some situations.

For example, blood tests may be done for several months for cancer antigen 15-3 (CA15-3) or cancer antibody 27.29 (CA27.29). These are very identical tests. One of these blood tests is regularly inspected, but not both.

The tumor marker test score’s increase or decrease over time may reveal information about the tumor’s reaction to treatment or the growth of the tumor ​5​.

Tumor marker testing is not always beneficial. Some individuals with rising tumor marker levels do not have tumor growth, whereas others with tumor growth have normal or stable tumor marker levels.

Treatment decisions aren’t made only based on serum tumor marker tests. They may combine the results of a tumor marker test with information about symptoms and imaging test results (such as bone scans). This information together can aid your health care specialists in determining whether or not a treatment is effective for your cancer.

If you want to know if tumor marker testing is correct for you, go to your doctor.

Hormonal therapy

HORMONE THERAPY and Background of Medicaments Composition, Stethoscope, mix therapy drugs doctor and select focus

Hormonal therapy, commonly known as endocrine therapy, is an effective treatment for many tumors that are ER or PR positive.

Hormones may be utilized by cancers with hormone receptors to fuel their growth. Hormonal therapy aims to diminish oestrogen and progesterone levels in the body or prevent these hormones from reaching cancer cells. Cancer will not mature if the hormones cannot get to the cancer cells.

Hormone treatment options consist of:

  • Tamoxifen 
  • Aromatase inhibitors
  • Ovarian suppression
  • Fulvestrant
  • Other hormonal therapies

Chemotherapy uses medications to kill cancer cells by preventing them from maturing, splitting, and producing new ones.

When a patient has been advised chemotherapy for metastatic breast cancer, it can be guided on various regimens, depending on what has worked best in clinical trials. It can be taken once a week, twice a week, three times a week, or even four times a week (also known as dose-dense). Weeks off are typically scheduled as a break in the weekly schedule. Chemotherapy is frequently continued if it helps combat cancer and the patient is not suffering from too many adverse effects.

Few drugs that are utilized for metastatic breast cancer are

  • Cisplatin
  • Doxorubicin
  • Epirubicin
  • Ixabepilone

Although each individual’s experience is different, many patients feel pretty well during chemotherapy treatment and take care of their family, travel, and exercise. Discuss the potential side effects of your chemotherapy strategy with your health care provider.


Immunotherapy can also be called Immuno oncology biologic therapy, a type of cancer medication that works by increasing the body’s immunity system. It improves, picks out or restores immune system function by using materials created by the body or laboratory. Immune checkpoint inhibitors, a kind of immunotherapy, treat recurring and advanced or metastatic breast cancer. Pembrolizumab is also utilized to treat high-risk, early-stage Metastatic Breast Cancer.

During an operation, the tumor and some surrounding healthy tissue are removed. In the case of metastatic breast cancer, surgery is not often used. Doctors may, however, suggest surgery to remove a tumor that is causing pain. Whether persons with metastatic breast cancer who have their primary breast tumor removed live longer is still being researched.

Breast cancer that has made its way to the brain can be medicated with surgery alone or radiation therapy. The goal is to reduce or temporarily eliminate brain malignancy. A neurosurgeon, a specialist who works on the head, brain, and central nervous system, usually performs this surgery.

Before surgery, talk to your doctor about the potential adverse effects of the procedure you’ll be having. Find out more about the fundamentals of cancer surgery.

Trop-2 antibody-drug conjugates

Antibody medicines that target specific cancer cells are available. Antibody-drug conjugates are antibody Metastatic Breast Cancer treatments containing a chemotherapeutic medication. The combination of these drugs enables targeted chemotherapeutic administration to particular cancer cells.

Cells in some breast tumors have more significant levels of the protein Trop-2 than in others (they express Trop-2) ​6​. Trop-2 is commonly expressed in triple-negative breast tumors.

Sacituzumab govitecan (Trodelvy)

Trop-2 antibody-drug conjugate Sacituzumab govitecan (Trodelvy). It’s a Trop-2 antibody and irinotecan, a chemotherapeutic medication. Due to this combination, irinotecan can be delivered to cancer cells that express Trop-2.

The FDA has approved sacituzumab govitecan to treat metastatic triple-negative breast tumors that have already been medicated with at least two pharmacological therapies in the metastatic setting.

Sacituzumab govitecan (Trodelvy) helps decrease tumors in patients with metastatic triple-negative breast cancers and may increase survival.

People with chronic conditions can benefit from disease management programmes, which are systematic Metastatic Breast Cancer treatments plan. They would want to give patients therapies that have been scientifically proven to help them and are tailored to their specific needs. Chronic disease patients should receive comprehensive care, advice, and information. Since 2002, Germany’s statutory health insurance funds have offered disease management projects.

Regular doctor’s appointments, consultations, and examinations are part of the programe. Participation is entirely voluntary and comes at no additional expense. People who participate in disease management projects, on the other hand, agree to participate in their Metastatic Breast Cancer treatments actively. The management projects include things like going to the doctor regularly. GPs and medical facilities who participate in these programes agree to meet specified quality standards. Health insurers are contacted to see if a disease management project for breast cancer is available.


  1. 1.
    Bonotto M, Gerratana L, Iacono D, et al. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? The Oncologist. Published online May 27, 2015:719-724. doi:10.1634/theoncologist.2015-0002
  2. 2.
    Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. Published online October 20, 2015:304-320. doi:10.1177/1758834015608993
  3. 3.
    Matutino A, Joy AA, Brezden-Masley C, Chia S, Verma S. Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. Current Oncology. Published online June 1, 2018:131-141. doi:10.3747/co.25.4000
  4. 4.
    Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res. Published online August 2, 2019:1342. doi:10.12688/f1000research.18888.1
  5. 5.
    Caffier H, Brandau H. Serum tumor markers in metastatic breast cancer and course of disease. Cancer Detect Prev. 1983;6(4-5):451-457.
  6. 6.
    Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. mAbs. Published online July 18, 2019:987-995. doi:10.1080/19420862.2019.1632115